Zentalis Pharmaceuticals, Inc.
ZNTL Nasdaq
SEC CIK 1725160
Follow Zentalis Pharmaceuticals
Weekly email: filings, results
Net income
−$28.8M
−8% vs same quarter last year
EPS, diluted
−$0.34
+8.1% vs same quarter last year
Operating cash flow
−$32.7M
−21.3% vs same quarter last year
Operating income
−$31.2M
+7.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$137.1M |
| FY24 | $67.4M | −$165.9M |
| FY23 | $0 | −$292.3M |
| FY22 | $0 | −$236.8M |
| FY21 | - | −$158.7M |
| FY20 | - | −$117.8M |
| FY19 | - | −$45.7M |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$125.2M |
| FY24 | −$171.1M |
| FY23 | −$208.4M |
| FY22 | −$166.3M |
| FY21 | −$160.2M |
| FY20 | −$87.6M |
| FY19 | −$39.5M |
| FY18 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $10M |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |